New combo therapy aims to turn inoperable lung cancer into a curable disease
NCT ID NCT07561983
First seen May 13, 2026 · Last updated May 24, 2026 · Updated 2 times
Summary
This study tests a new approach for people with stage III non-small cell lung cancer that cannot be removed with surgery. Participants receive a combination of an immunotherapy drug (tislelizumab), standard chemotherapy, and a targeted procedure that delivers chemotherapy directly to the lung tumor's blood supply. The goal is to shrink the tumor enough so that it can be surgically removed, potentially improving long-term outcomes. The trial will monitor how many patients become eligible for surgery and how long they remain free of cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TISLELIZUMAB are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sichuan Cancer Hospital and Research Institute
Chengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.